Skip to main content
S&P 5007,773.95+0.66%DOW51,267.90+0.18%NASDAQ27,477.31+1.05%BTC$85,798.00-0.92%ETH$2,712.38-0.63%GOLD$4,164.00+0.17%OIL$89.47+0.04%
Smart Investors Daily
SID Premium
SU

NASDAQ · SUPN

Supernus Pharmaceuticals, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$42.38

Up+$0.38 (+0.90%)

Updated Oct 6, 2026, 12:42 AM

SID Score

5.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.6B
P/E ratio
-137.62
Dividend yield
0.00%
52-week range
$40.51 – $59.68
Volume
739.81K
Avg. volume
851.65K

Price performance · SUPN

SUPN price history

1M range · 19 trading sessions · Daily adjusted prices

Prices through Oct 2, 2026

SUPN closed at $42.38 after 19 trading sessions, down 0.12% for the selected period.

Last close
$42.38
Period change
-0.12%
Period low
$41.28
Period high
$44.60
Daily close
View OHLC price history
SUPN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 2, 2026$42.47$43.15$41.88$42.38739.81K
Oct 1, 2026$43.21$43.685$42.15$42.18424.63K
Sep 30, 2026$44.03$44.18$43.03$43.04685.59K
Sep 29, 2026$44.39$44.93$43.20$43.97551.6K
Sep 28, 2026$42.59$44.61$42.38$44.60731.23K
Sep 25, 2026$43.21$43.69$42.65$42.66607.57K
Sep 24, 2026$43.22$44.00$42.765$43.29589.01K
Sep 23, 2026$43.66$44.4575$43.14$43.39544.53K
Sep 22, 2026$43.04$44.25$42.82$43.75667.59K
Sep 21, 2026$42.00$42.97$41.68$42.78635.72K
Sep 18, 2026$42.89$42.89$41.60$42.001.18M
Sep 17, 2026$41.66$43.40$41.46$42.92559.77K
Sep 16, 2026$41.31$41.84$40.75$41.38787.82K
Sep 15, 2026$41.49$41.75$40.51$41.28669.22K
Sep 14, 2026$42.16$42.5429$41.23$41.49678.06K
Sep 11, 2026$41.81$42.44$41.62$41.64707.16K
Sep 10, 2026$41.84$42.55$41.11$41.69726.75K
Sep 9, 2026$42.17$42.59$41.50$42.07580.43K
Sep 8, 2026$43.56$43.56$42.32$42.43429.13K

Latest SUPN news

The latest Smart Investors Daily articles mentioning SUPN.

Stock researchCompany · Overview

SUPN research

Overview

Company profile and research snapshot.

Company profile

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$64.00
Implied upside
—
Analysts
12
SUPN recent ratings
DateFirmRatingTarget
Jul 9, 2026Cantor FitzgeraldOverweight—
Dec 19, 2025StifelHold—
Oct 29, 2025B of A SecuritiesBuy—
Oct 23, 2025TD CowenBuy—
Oct 9, 2025Piper SandlerOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 19, 2026

Why Did Supernus Pharmaceuticals (SUPN) Move Today?

Supernus Pharmaceuticals (SUPN) is back in focus after reporting Q2 revenue of US$211.3 million, up 27.7% year on year, beating expectations and nudging full-year guidance higher on what management described as sustained product momentum. The upbeat quarter comes amid a more challenging period for Supernus Pharmaceuticals, with the share price down 15.1% year to date and about 13.5% lower over the past month, even though the 3-year total shareholder return of roughly 49% still points to a...

Yahoo · Sep 18, 2026

How Supernus’ Q2 Beat and Raised Guidance Could Reshape Supernus Pharmaceuticals (SUPN) Investors’ Outlook

In Q2 2026, Supernus Pharmaceuticals reported revenues of US$211.3 million, a 27.7% year-on-year increase, and raised its full-year revenue and operating income guidance above analyst expectations, citing strong performance from growth products and effective commercial execution. This combination of outperformance and upgraded guidance suggests Supernus’s existing CNS portfolio is scaling efficiently, reinforcing management’s confidence in the company’s current commercial model. With...

Yahoo · Sep 8, 2026

1 of Wall Street’s Favorite Stocks with Promising Prospects and 2 Facing Headwinds

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By